.png | image2 = Nimodipine.gif | width = 194 | CAS_number = 66085-59-4 | ATC_prefix = C08 | ATC_suffix = CA06 | ATC_supplemental = | PubChem = 4497 | DrugBank = APRD00612 | chemical_formula = C₂₁H₂₆N₂O₇ | molecular_weight = 418.44 g/mol | smiles = | melting_point = 7 | bioavailability = 100% (Intravenous) 13% (Oral) | protein_bound = 95% | metabolism = Hepatic | elimination_half-life = 8-9 hours | pregnancy_category = C: (USA) | legal_status = | routes_of_administration = Intravenous, Oral }}

Nimodipine (marketed by Bayer as Nimotop®) is a dihydropyridine calcium channel blocker originally developed for the treatment of high blood pressure. It is not frequently used for this indication, but has shown good results in preventing a major complication of subarachnoid hemorrhage (a form of cerebral hemorrhage) termed vasospasm; this is now the main use of nimodipine.

Dosage

---

The regular dosage is 60 mg tablets four times daily. If the patient is unable to take tablets orally, it is given via intravenous infusion at a rate of 0.5-1 mg/hour (lower dosage if the body weight is <70 kg or blood pressure is too low).

More on [ Nimodipine ]

Subscribe to Nimodipine RSS feed